Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 01, 2008 (Vol. 28, No. 19)


  • Much useful information
  • Poor organization
This site is hosted by ExonHit Therapeutics, an enterprise that focuses on alternative RNA splicing with several products in development. These include a small molecule in Phase II development for Alzheimer’s disease. The site is not just about the company’s products, however. One informative section discusses RNA splicing. Another elaborates about medical applications for which alternative splicing has health consequences, and these make for interesting reading. An online search engine called Splice Array Portal gives researchers important tools to measure/detect differences between alternatively spliced mRNAs. A set of tutorials is also available, as is an informative FAQ section. A commercial site with a gentle, rather than an overwhelming approach to its subject, ExonHit is a very useful site. I just hope they manage to get over the numerous FDA hurdles enroute to approval for the drugs they are designing.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »